GlassScriptPhysician profile
Eudaldo Aponte
NPI 1720450166
$214,399.76
in general payments reported to CMS, 2019-2025
17 companies · $34K in 2025
The $34K reported for 2025 was more than what 99% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $52K · 2022: $32K · 2023: $63K · 2024: $34K · 2025: $34K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $112K · Travel and Lodging: $10K · Food and Beverage: $8,079 · Consulting Fee: $330 · Education: $78.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $112,100.25 |
| Travel and Lodging | $10,149.89 |
| Food and Beverage | $8,079.12 |
| Consulting Fee | $330.00 |
| Education | $78.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $81,013.23 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $73,637.39 | 2021-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Alkermes, INC. | $29,694.94 | 2021-2025 | Aristada, Aristada Initio, Lybalvi |
| Janssen Pharmaceuticals, INC | $14,052.23 | 2021-2024 | Invega Sustenna, Invega Trinza, Invega |
| Otsuka America Pharmaceutical, INC. | $6,972.33 | 2021-2024 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Neurocrine Biosciences, INC. | $4,651.69 | 2021-2025 | Ingrezza |
| Allergan, INC. | $1,925.00 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,040.34 | 2021-2025 | Caplyta |
| Bausch Health US, LLC | $280.22 | 2023-2025 | Aplenzin |
| Vanda Pharmaceuticals INC. | $240.23 | 2021-2025 | Fanapt, Hetlioz |
| Takeda Pharmaceuticals U.S.A., INC. | $214.58 | 2024-2025 | Trintellix |
| Axsome Therapeutics, INC. | $190.56 | 2024-2025 | Auvelity |
| Sunovion Pharmaceuticals INC. | $163.64 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $157.65 | 2024-2025 | Qelbree |
| Lundbeck LLC | $86.46 | 2021-2023 | Rexulti |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $67.10 | 2025 | Cobenfy |
| Indivior INC. | $12.17 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eudaldo Aponte listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.